|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Tysabri-ROW
As previously mentioned, in the ROW market, Biogen Idec is
responsible for distribution and we record as revenue our share
of the profit or loss on ROW sales of Tysabri, plus our
directly incurred expenses on these sales. In 2008, we recorded
ROW revenue of $135.5 million (2007: $14.3 million;
2006: negative revenue of $10.7 million), which was
calculated as follows (in millions):
As of the end of December 2008, approximately
16,900 patients, principally in the European Union, were on
commercial Tysabri therapy, an increase of 125% compared
to approximately 7,500 patients at the end of December 2007.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Tysabri-ROW
As previously mentioned, in the ROW market, Biogen Idec is
responsible for distribution and we record as revenue our share
of the profit or loss on ROW sales of Tysabri, plus our
directly-incurred expenses on these sales. In 2007, Elan
recorded ROW revenue of $14.3 million (2006: negative
revenue of $10.7 million), which was calculated as follows
(in millions):
As of the end of December 2007, approximately
7,500 patients, principally in the European Union, were on
commercial Tysabri therapy.
Maxipime revenue decreased 23% to $122.5 million in
2007 from our 2006 sales level and increased 14% to
$159.9 million in 2006 from our 2005 sales level. The
decrease in 2007 was principally due to the introduction of
generic competition. In June 2007, the first generic formulation
of cefepime hydrochloride was approved by the FDA. Generic
cefepime hydrochloride was launched shortly thereafter, and we
expect it will continue to materially and adversely affect our
revenues from, and gross margin for, Maxipime. The
increase in Maxipime revenue in 2006 from our 2005 sales
level reflected growth in the demand for the product and was
partially offset by supply shortages in 2006.
Azactam revenue increased 11% to $86.3 million in
2007 from our 2006 sales level and increased 35% to
$77.9 million in 2006 from our 2005 sales level. The
increases in 2007 and 2006 were primarily due to increased
demand. Azactam lost its patent exclusivity in October
2005, and its future sales are expected to be negatively
impacted by generic competition, although to date no generic
form of Azactam has been approved.
Table of Contents
Prialt revenue increased 2% to $12.3 million in 2007
from our 2006 sales level and increased 92% to
$12.1 million in 2006 from our 2005 sales level. The
increases in both 2007 and 2006 were primarily due to increased
demand. Prialt was launched in the U.S. market in
the first quarter of 2005. In March 2006, we completed
the sale of the European rights to Prialt to Eisai, while
retaining the product rights in the United States. We had not
made any commercial sales of Prialt in Europe prior to
this divestment.
| EXCERPTS ON THIS PAGE:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
